Randomized controlled trial of intraputamenal glial cell line–derived neurotrophic factor infusion in Parkinson disease
暂无分享,去创建一个
Mark Stacy | Gary Hotton | Vijay Dhawan | Richard Penn | Elena Moro | Kim Burchiel | Michael Traub | J. Nutt | R. Penn | P. Kelly | A. Lang | A. Lozano | E. Moro | D. Brooks | V. Dhawan | R. Coffey | M. Stacy | D. Turner | E. Laws | S. Gill | N. Patel | G. Hotton | P. Heywood | B. Scott | M. Brodsky | A. Stoessl | K. Burchiel | W. J. Elias | A. Jon Stoessl | J. Matcham | David J. Brooks | James Matcham | Peter Heywood | John G. Nutt | Anthony E. Lang | Steven Gill | Nik K. Patel | Andres Lozano | Matthew A. Brodsky | Patrick Kelly | Arif Dalvi | Burton Scott | Dennis Turner | V. G. Frederich Wooten | William J. Elias | Edward R. Laws | Robert J. Coffey | M. Traub | Arif Dalvi | V. Wooten | W. Elias | V. G. F. Wooten
[1] Richard Grondin,et al. Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. , 2002, Brain : a journal of neurology.
[2] C. Olanow,et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. , 2001, The New England journal of medicine.
[3] D. Brooks,et al. Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease , 2003, Nature Medicine.
[4] B. Davidson,et al. Dopaminergic Neurons Protected from Degeneration by GDNF Gene Therapy , 1997, Science.
[5] S. Gill,et al. Intraputamenal infusion of glial cell line–derived neurotrophic factor in PD: A two‐year outcome study , 2005, Annals of neurology.
[6] J. Jankovic,et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD , 2003, Neurology.
[7] J. Lile,et al. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. , 1993, Science.
[8] G. Gerhardt,et al. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. , 2005, Journal of neurosurgery.
[9] D. Russell,et al. Effects of perceived treatment on quality of life and medical outcomes in a double-blind placebo surgery trial. , 2004, Archives of general psychiatry.
[10] Timothy Sendera,et al. Clinicopathological findings following intraventricular glial‐derived neurotrophic factor treatment in a patient with Parkinson's disease , 1999, Annals of neurology.
[11] D. Brooks,et al. Core assessment program for intracerebral transplantations (CAPIT) , 1992, Movement disorders : official journal of the Movement Disorder Society.
[12] D. Brooks,et al. Glial cell line–derived neurotrophic factor induces neuronal sprouting in human brain , 2005, Nature Medicine.
[13] J. Bloch,et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. , 2000, Science.
[14] C D Marsden,et al. Differing patterns of striatal 18F‐dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy , 1990, Annals of neurology.
[15] Vesna Sossi,et al. A double‐blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease , 2003, Annals of neurology.
[16] R. Bakay,et al. Lentivirally Delivered Glial Cell Line-Derived Neurotrophic Factor Increases the Number of Striatal Dopaminergic Neurons in Primate Models of Nigrostriatal Degeneration , 2002, The Journal of Neuroscience.